The Critical Medicines Act has cleared its biggest political hurdle, yet the real test of Europe’s plan to protect hospital supplies still lies ahead. Parliament and Council negotiators reached a provisional agreement in the early hours of 12 May 2026 on the regulation, which builds on the Commission proposal COM(2025)102. Final endorsement by both institutions is expected over the coming months, and publication in the Official Journal is likely towards the end of 2026, according to a legal analysis of the deal.
The Critical Medicines Act aims to reduce shortages by strengthening production and supply of medicines that health systems cannot do without. Its core idea is a mix of procurement rules and incentives that favour manufacturing in Europe. Public buyers will have to apply resilience requirements when they purchase critical medicines, rather than choosing the cheapest bid alone.
The agreement also introduces what negotiators call an EU preference. Companies can receive rewards in proportion to the share of a medicine and its active pharmaceutical ingredient made inside the Union. Strategic projects, which the Act will designate under agreed criteria, must meet clear conditions if they receive public support, including prioritising supply to the EU market.
Joint purchasing is another pillar. Negotiators cut the number of member states needed to trigger a collaborative procurement request from nine to five, which should make joint tenders far easier to launch. Orphan medicines, defined as treatments for conditions affecting no more than five in 10,000 people in the EU, now fall within the scope of strategic projects and collaborative procurement.
Not every Parliament demand survived. Lawmakers wanted a mandatory coordination mechanism for contingency stocks, but the final text keeps information sharing voluntary. The existing voluntary solidarity mechanism will carry new data-sharing measures and help reallocate medicines between countries when shortages bite. Patient groups and some MEPs may regard that as a missed chance, while several governments will welcome the flexibility.
The Commission and the European Medicines Agency both welcomed the Critical Medicines Act, and the industry reaction is mixed. Generic makers hope the procurement rules will finally reward reliable supply instead of rock-bottom prices. Others warn that incentives only work if member states fund them, and that depends on national health budgets already under pressure.
Hospitals will feel the effects first. Shortages of antibiotics and cancer treatments have repeatedly worried health ministers, and the Critical Medicines Act targets exactly those product groups through procurement rules and stock sharing. Ministers therefore see the Critical Medicines Act as a practical supply tool as well as an industrial policy instrument.
The Act also sits beside the pharmaceutical reform package, which the institutions expect to publish later in 2026. Together the two files will reshape how Europe regulates, buys and secures medicines for the rest of the decade. Companies preparing bids should watch the final legal text, because the application date remains to be confirmed.
For patients, the promise is simple: fewer empty shelves and fewer cancelled treatments. Whether the Critical Medicines Act keeps that promise will depend on endorsement votes this winter, on national funding choices, and on how quickly joint tenders appear.
